Why These 5 Stocks Are on the Move on Wednesday

4. Incyte Corporation (NASDAQ:INCY) has fallen around 6% after the FDA approved Incyte Corporation (NASDAQ:INCY)’s Opzelura for the topical treatment for mild to moderate atopic dermatitis, in patients 12 and older. Hurting Incyte Corporation (NASDAQ:INCY) shares could be that the approval is contingent on a ‘boxed warning’ over JAK inhibitors and risks over heart problems and potentially serious infections. Julian Baker And Felix Baker’s Baker Bros. Advisors was long around 32.02 million shares of Incyte Corporation (NASDAQ:INCY) at the end of June.